India, April 15 -- Aligos Therapeutics, Inc. (ALGS) announced encouraging first interim results from its Phase 2 B-SUPREME study of Pevifoscorvir sodium in adults with chronic hepatitis B virus (HBV) infection.
The independent Data Safety Monitoring Review Board (DSMB) recommended continuing the study and increasing enrolment in the HBeAg-negative cohort to strengthen statistical power, noting that futility criteria were not met.
Chronic HBV affects more than 250 million people worldwide and remains a leading cause of liver cancer. Current therapies often suppress but rarely eliminate the virus, leaving a significant unmet need.
The B-SUPREME trial is a randomized, double-blind, multicentre study comparing Pevifoscorvir sodium monotherap...